Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma: A Multicenter Registry-Based Study.
AJCC
Advanced
Chemotherapy
Enucleation
International
Metastasis
Multicenter
Registry
Retinoblastoma
Staging
Journal
Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
19
03
2022
revised:
12
04
2022
accepted:
25
04
2022
pubmed:
3
5
2022
medline:
27
7
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
To evaluate presenting features, tumor size, and treatment methods for risk of metastatic death due to advanced intraocular retinoblastoma (RB). International, multicenter, registry-based retrospective case series. A total of 1841 patients with advanced RB. Advanced RB was defined by 8th edition American Joint Committee on Cancer (AJCC) categories cT2 and cT3 and new AJCC-Ophthalmic Oncology Task Force (OOTF) Size Groups (1: < 50% of globe volume, 2: > 50% but < 2/3, 3: > 2/3, and 4: diffuse infiltrating RB). Treatments were primary enucleation, systemic chemotherapy with secondary enucleation, and systemic chemotherapy with eye salvage. Metastatic death. The 5-year Kaplan-Meier cumulative survival estimates by patient-level AJCC clinical subcategories were 98% for cT2a, 96% for cT2b, 88% for cT3a, 95% for cT3b, 92% for cT3c, 84% for cT3d, and 75% for cT3e RB. Survival estimates by treatment modality were 96% for primary enucleation, 89% for systemic chemotherapy and secondary enucleation, and 90% for systemic chemotherapy with eye salvage. Risk of metastatic mortality increased with increasing cT subcategory (P < 0.001). Cox proportional hazards regression analysis confirmed a higher risk of metastatic mortality in categories cT3c (glaucoma, hazard ratio [HR], 4.9; P = 0.011), cT3d (intraocular hemorrhage, HR, 14.0; P < 0.001), and cT3e (orbital cellulitis, HR, 19.6; P < 0.001) than in category cT2a and with systemic chemotherapy with secondary enucleation (HR, 3.3; P < 0.001) and eye salvage (HR, 4.9; P < 0.001) than with primary enucleation. The 5-year Kaplan-Meier cumulative survival estimates by AJCC-OOTF Size Groups 1 to 4 were 99%, 96%, 94%, and 83%, respectively. Mortality from metastatic RB increased with increasing Size Group (P < 0.001). Cox proportional hazards regression analysis revealed that patients with Size Group 3 (HR, 10.0; P = 0.002) and 4 (HR, 41.1; P < 0.001) had a greater risk of metastatic mortality than Size Group 1. The AJCC-RB cT2 and cT3 subcategories and size-based AJCC-OOTF Groups 3 (> 2/3 globe volume) and 4 (diffuse infiltrating RB) provided a robust stratification of clinical risk for metastatic death in advanced intraocular RB. Primary enucleation offered the highest survival rates for patients with advanced intraocular RB.
Identifiants
pubmed: 35500608
pii: S0161-6420(22)00310-4
doi: 10.1016/j.ophtha.2022.04.022
pmc: PMC9329221
mid: NIHMS1816535
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
933-945Subventions
Organisme : NCI NIH HHS
ID : K08 CA232344
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Références
Ophthalmology. 2021 May;128(5):740-753
pubmed: 33007338
Br J Ophthalmol. 1960 Jan;44:35-41
pubmed: 14443414
Ophthalmology. 2003 Jan;110(1):13-4
pubmed: 12511339
Int J Ophthalmol. 2017 Jun 18;10(6):961-967
pubmed: 28730089
Pediatr Blood Cancer. 2012 Mar;58(3):356-61
pubmed: 21721113
Am J Ophthalmol. 2004 May;137(5):944-6
pubmed: 15126167
Eye (Lond). 2016 Jan;30(1):46-52
pubmed: 26427984
Int Ophthalmol Clin. 2019 Spring;59(2):77-86
pubmed: 30908281
Ophthalmology. 2015 Jun;122(6):1165-72
pubmed: 25841975
Lancet Glob Health. 2022 Mar;10(3):e307-e308
pubmed: 35093203
Pediatr Blood Cancer. 2008 Jan;50(1):160-2
pubmed: 17120241
Ophthalmology. 2020 Dec;127(12):1719-1732
pubmed: 32512116
Ophthalmology. 2006 Dec;113(12):2276-80
pubmed: 16996605
J Pediatr Hematol Oncol. 2009 May;31(5):325-9
pubmed: 19415010
Ophthalmol Retina. 2017 Jul - Aug;1(4):263-265
pubmed: 31047507
Cancers (Basel). 2021 Feb 08;13(4):
pubmed: 33567541
Prog Retin Eye Res. 2019 Nov;73:100764
pubmed: 31173880
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii
pubmed: 15763190
Surv Ophthalmol. 2002 Jan-Feb;47(1):1-16
pubmed: 11801265
JAMA Oncol. 2020 May 1;6(5):685-695
pubmed: 32105305
Ophthalmology. 2020 Dec;127(12):1733-1746
pubmed: 32526306
Ophthalmology. 2022 Aug;129(8):923-932
pubmed: 35436535
Acta Ophthalmol. 2020 Feb;98(1):e121-e125
pubmed: 31421017
Ophthalmology. 2019 Sep;126(9):1306-1314
pubmed: 30986443
Ocul Oncol Pathol. 2016 Apr;2(3):128-32
pubmed: 27239450